Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
argenx SE

argenx SE (ARGX) Stock Overview

Explore argenx SE’s financial performance, market position, analyst ratings, and future outlook.

ARGX●NASDAQ
HealthcareBiotechnology
$1038.12
$5.26(0.51%)
U.S. Market opens in 1h 26m

argenx SE (ARGX)

Meyka AI Score

Z

Key Financials

Market Cap64.6B
P/E Ratio27.73
EPS (TTM)$11.08
ROE0.32%
Fundamental Analysis

AI Price Forecasts

1 Month$1032.98
3 Months$1089.60
1 Year Target$878.89

ARGX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of argenx SE (NASDAQ: ARGX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of A, argenx SE's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of ARGX on the NASDAQ shows an RSI of 73.28, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $878.89 for the NASDAQ listing.

Key metrics behind argenx SE's NASDAQ-traded stock include a P/E ratio of 27.73 and a market capitalization of 64.6B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ARGX on the NASDAQ.

Price Performance (NASDAQ: ARGX)

1-Day Change
0.51%
5-Day Change
22.80%
1-Month Change
22.68%
3-Month Change
29.08%
6-Month Change
22.94%
Year-to-Date (YTD) Change
23.45%
1-Year Change
57.06%
3-Year Change
105.88%
5-Year Change
230.002%
All-Time (Max) Change
4413.57%

Contact Information

http://www.argenx.com
31 10 703 8441
Laarderhoogtweg 25, Amsterdam, NH, 1101EB

Company Facts

18,630 Employees
IPO DateMay 18, 2017
CountryNL
Actively Trading

Frequently Asked Questions